Meta-analysis of increased heart rate and blood pressure associated with CNS stimulant treatment of ADHD in adults

European Neuropsychopharmacology

Volumn 23, Issue 6, 2013, Pages 534-541

  Mick, Eric ^a   McManus, David D ^a   Goldberg, Robert J ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

ADHD; Adult; Blood pressure; CNS stimulants; Elevated heart rate

Indexed keywords

AMPHETAMINE DERIVATIVE; DEXMETHYLPHENIDATE; LISDEXAMFETAMINE; METHYLPHENIDATE;

ARTICLE; ATTENTION DEFICIT DISORDER; CARDIOVASCULAR PARAMETERS; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); DIASTOLIC BLOOD PRESSURE; DRUG DOSE TITRATION; DRUG MEGADOSE; DRUG SAFETY; ELECTROCARDIOGRAM; HEART PROTECTION; HEART RATE; HUMAN; LOW DRUG DOSE; META ANALYSIS; MORBIDITY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZATION; REST; RISK ASSESSMENT; SIDE EFFECT; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION;

ADULT; AGED; AGING; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BLOOD PRESSURE; CENTRAL NERVOUS SYSTEM STIMULANTS; HEART RATE; HUMANS; HYPERTENSION; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TACHYCARDIA;

EID: 84877924649     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2012.06.011     Document Type: Article

References (49)

1. Adler L.A., Goodman D.W., Kollins S.H., Weisler R.H., Krishnan S., Zhang Y., Biederman J. Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. J. Clin. Psychiatry 2008, 69:1364-1373.
2. Adler L.A., Weisler R.H., Goodman D.W., Hamdani M., Niebler G.E. Short-term effects of lisdexamfetamine dimesylate on cardiovascular parameters in a 4-week clinical trial in adults with attention-deficit/hyperactivity disorder. J. Clin. Psychiatry 2009, 70:1652-1661.
3. Adler L.A., Zimmerman B., Starr H.L., Silber S., Palumbo J., Orman C., Spencer T. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study. J. Clin. Psychopharmacol. 2009, 29:239-247.
4. Akinbami L.J., Liu X., Pastor P.N., Reuben C.A. Attention deficit hyperactivity disorder among children aged 5-17 years in the United States, 1998-2009. NCHS Data Brief 2011, 1-8.
5. Biederman J., Fried R., Hammerness P., Surman C., Mehler B., Petty C.R., Faraone S.V., Miller C., Bourgeois M., Meller B., Godfrey K.M., Reimer B. The effects of lisdexamfetamine dimesylate on the driving performance of young adults with ADHD: a randomized, double-blind, placebo-controlled study using a validated driving simulator paradigm. J. Psychiatr. Res 2012.
6. Biederman J., Mick E., Surman C., Doyle R., Hammerness P., Harpold T., Dunkel S., Dougherty M., Aleardi M., Spencer T. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol. Psychiatry 2006, 59:829-835.
7. Biederman J., Mick E., Surman C., Doyle R., Hammerness P., Kotarski M., Spencer T. A randomized, 3-phase, 34-week, double-blind, long-term efficacy study of osmotic-release oral system-methylphenidate in adults with attention-deficit/hyperactivity disorder. J. Clin. Psychopharmacol. 2010, 30:549-553.
8. Biederman J., Mick E.O., Surman C., Doyle R., Hammerness P., Michel E., Martin J., Spencer T.J. Comparative acute efficacy and tolerability of OROS and immediate release formulations of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. BMC Psychiatry 2007, 7:49.
9. Casas M., Rosler M., Sandra Kooij J.J., Ginsberg Y., Ramos-Quiroga J.A., Heger S., Berwaerts J., Dejonckheere J., Van Der Vorst E., Schauble B. Efficacy and safety of prolonged-release OROS methylphenidate in adults with attention deficit/hyperactivity disorder: a 13-week, randomized, double-blind, placebo-controlled, fixed-dose study. World J. Biol. Psychiatry 2011.
10. Cooney M.T., Vartiainen E., Laatikainen T., Juolevi A., Dudina A., Graham I.M. Elevated resting heart rate is an independent risk factor for cardiovascular disease in healthy men and women. Am. Heart J. 2010, 159:612-619 e3.
11. Cooper W.O., Habel L.A., Sox C.M., Chan K.A., Arbogast P.G., Cheetham T.C., Murray K.T., Quinn V.P., Stein C.M., Callahan S.T., Fireman B.H., Fish F.A., Kirshner H.S., O'duffy A., Connell F.A., Ray W.A. ADHD drugs and serious cardiovascular events in children and young adults. N. Engl. J. Med. 2011, 365:1896-1904.
12. De Zwaan M., Gruss B., Muller A., Philipsen A., Graap H., Martin A., Glaesmer H., Hilbert A. Association between obesity and adult attention-deficit/hyperactivity disorder in a German community-based sample. Obes. Facts 2011, 4:204-211.
13. Denchev P., Kaltman J.R., Schoenbaum M., Vitiello B. Modeled economic evaluation of alternative strategies to reduce sudden cardiac death among children treated for attention deficit/hyperactivity disorder. Circulation 2010, 121:1329-1337.
14. Faraone S.V., Biederman J., Mick E. The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychol. Med. 2006, 36:159-165.
15. Faraone S.V., Glatt S.J. A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes. J. Clin. Psychiatry 2009, 71:754-763.
16. Fox K., Ford I., Steg P.G., Tendera M., Robertson M., Ferrari R. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet 2008, 372:817-821.
17. Franke B., Faraone S.V., Asherson P., Buitelaar J., Bau C.H., Ramos-Quiroga J.A., Mick E., Grevet E.H., Johansson S., Haavik J., Lesch K.P., Cormand B., Reif A. The genetics of attention deficit/hyperactivity disorder in adults, a review. Mol. Psychiatry 2011.
18. Gerhard T., Winterstein A.G., Olfson M., Huang C., Saidi A., Crystal S. Pre-existing cardiovascular conditions and pharmacological treatment of adult ADHD. Pharmacoepidemiol. Drug Saf. 2010, 19:457-464.
19. Gould M.S., Walsh B.T., Munfakh J.L., Kleinman M., Duan N., Olfson M., Greenhill L., Cooper T. Sudden death and use of stimulant medications in youths. Am. J. Psychiatry 2009, 166:992-1001.
20. Habel L.A., Cooper W.O., Sox C.M., Chan K.A., Fireman B.H., Arbogast P.G., Cheetham T.C., Quinn V.P., Dublin S., Boudreau D.M., Andrade S.E., Pawloski P.A., Raebel M.A., Smith D.H., Achacoso N., Uratsu C., Go A.S., Sidney S., Nguyen-Huynh M.N., Ray W.A., Selby J.V. ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. JAMA 2011, (306):2673-2683.
21. Hammerness P., Zusman R., Systrom D., Surman C., Baggish A., Schillinger M., Shelley-Abrahamson R., Wilens T.E. A cardiopulmonary study of lisdexamfetamine in adults with attention-deficit/hyperactivity disorder. World J. Biol. Psychiatry 2012.
22. Hammerness P.G., Surman C.B., Chilton A. Adult attention-deficit/hyperactivity disorder treatment and cardiovascular implications. Curr. Psychiatry Rep. 2011, 13:357-363.
23. Harbord R.M., Higgins J.P.T. Meta-regression in Stata. Stata J. 2008, 8:493-519.
24. Hozawa A., Ohkubo T., Kikuya M., Ugajin T., Yamaguchi J., Asayama K., Metoki H., Ohmori K., Hoshi H., Hashimoto J., Satoh H., Tsuji I., Imai Y. Prognostic value of home heart rate for cardiovascular mortality in the general population: the Ohasama study. Am. J. Hypertens. 2004, 17:1005-1010.
25. Kessler R.C., Adler L., Barkley R., Biederman J., Conners C.K., Demler O., Faraone S.V., Greenhill L.L., Howes M.J., Secnik K., Spencer T., Ustun T.B., Walters E.E., Zaslavsky A.M. The prevalence and correlates of adult ADHD in the United States: results from the national comorbidity survey replication. Am. J. Psychiatry 2006, 163:716-723.
26. Kooij J.J., Burger H., Boonstra A.M., Van Der Linden P.D., Kalma L.E., Buitelaar J.K. Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder. A randomized placebo-controlled double-blind cross-over trial. Psychol. Med. 2004, 34:973-982.
27. Matthies S., Holzner S., Feige B., Scheel C., Perlov E., Ebert D., Tebartz Van Elst L., Philipsen A. ADHD as a serious risk factor for early smoking and nicotine dependence in adulthood. J. Atten. Disord 2012.
28. Mccarthy S., Cranswick N., Potts L., Taylor E., Wong I.C. Mortality associated with attention-deficit hyperactivity disorder (ADHD) drug treatment: a retrospective cohort study of children, adolescents and young adults using the general practice research database. Drug Saf. 2009, 32:1089-1096.
29. Medco, 2011. America's State of Mind. , November 10 2011. http://medco.mediaroom.com.
30. Medori R., Ramos-Quiroga J.A., Casas M., Kooij J.J., Niemela A., Trott G.E., Lee E., Buitelaar J.K. A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol. Psychiatry 2008, 63:981-989.
31. Perret-Guillaume C., Joly L., Benetos A. Heart rate as a risk factor for cardiovascular disease. Prog. Cardiovasc. Dis. 2009, 52:6-10.
32. Polanczyk G., De Lima M.S., Horta B.L., Biederman J., Rohde L.A. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am. J. Psychiatry 2007, 164:942-948.
33. Reimherr F.W., Williams E.D., Strong R.E., Mestas R., Soni P., Marchant B.K. A double-blind, placebo-controlled, crossover study of osmotic release oral system methylphenidate in adults with ADHD with assessment of oppositional and emotional dimensions of the disorder. J. Clin. Psychiatry 2007, 68:93-101.
34. Retz W., Rosler M., Ose C., Scherag A., Alm B., Philipsen A., Fischer R., Ammer R. Multiscale assessment of treatment efficacy in adults with ADHD: a randomized placebo-controlled, multi-centre study with extended-release methylphenidate. World J. Biol. Psychiatry 2012, 13:48-59.
35. Rosler M., Fischer R., Ammer R., Ose C., Retz W. A randomised, placebo-controlled, 24-week, study of low-dose extended-release methylphenidate in adults with attention-deficit/hyperactivity disorder. Eur. Arch. Psychiatry Clin. Neurosci. 2009, 259:120-129.
36. Schelleman H., Bilker W.B., Strom B.L., Kimmel S.E., Newcomb C., Guevara J.P., Daniel G.W., Cziraky M.J., Hennessy S. Cardiovascular events and death in children exposed and unexposed to ADHD agents. Pediatrics 2011, 127:1102-1110.
37. Sharp S., Sterne J. New syntax and output for the meta-analysis command. Stata Tech. Bull. 1998, 42:6-8.
38. Simon V., Czobor P., Balint S., Meszaros A., Bitter I. Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis. Br. J. Psychiatry 2009, 194:204-211.
39. Spencer T., Biederman J., Wilens T., Doyle R., Surman C., Prince J., Mick E., Aleardi M., Herzig K., Faraone S. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biol. Psychiatry 2005, 57:456-463.
40. Spencer T., Biederman J., Wilens T., Faraone S., Prince J., Gerard K., Doyle R., Parekh A., Kagan J., Bearman S.K. Efficacy of a mixed amphetamine salts compound in adults with attention-deficit/hyperactivity disorder. Arch. Gen. Psychiatry 2001, 58:775-782.
41. Spencer T., Wilens T., Biederman J., Faraone S.V., Ablon J.S., Lapey K. A double-blind, crossover comparison of methylphenidate and placebo in adults with childhood-onset attention-deficit hyperactivity disorder. Arch. Gen. Psychiatry 1995, 52:434-443.
42. Spencer T.J., Adler L.A., Mcgough J.J., Muniz R., Jiang H., Pestreich L. Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit/hyperactivity disorder. Biol. Psychiatry 2007, 61:1380-1387.
43. Taylor F.B., Russo J. Efficacy of modafinil compared to dextroamphetamine for the treatment of attention deficit hyperactivity disorder in adults. J. Child Adolesc. Psychopharmacol. 2000, 10:311-320.
44. Thompson S.G., Sharp S.J. Explaining heterogeneity in meta-analysis: a comparison of methods. Stat. Med. 1999, 18:2693-2708.
45. Weisler R.H., Biederman J., Spencer T.J., Wilens T.E., Faraone S.V., Chrisman A.K., Read S.C., Tulloch S.J. Mixed amphetamine salts extended-release in the treatment of adult ADHD: a randomized, controlled trial. CNS Spectr. 2006, 11:625-639.
46. Weiss M., Hechtman L. A randomized double-blind trial of paroxetine and/or dextroamphetamine and problem-focused therapy for attention-deficit/hyperactivity disorder in adults. J. Clin. Psychiatry 2006, 67:611-619.
47. Wender P.H., Reimherr F.W., Wood D., Ward M. A controlled study of methylphenidate in the treatment of attention deficit disorder, residual type, in adults. Am. J. Psychiatry 1985, 142:547-552.
48. Wilens T.E., Martelon M., Joshi G., Bateman C., Fried R., Petty C., Biederman J. Does ADHD predict substance-use disorders? A 10-year follow-up study of young adults with ADHD. J. Am. Acad. Child Adolesc. Psychiatry 2011, 50:543-553.
49. Winterstein A.G., Gerhard T., Shuster J., Johnson M., Zito J.M., Saidi A. Cardiac safety of central nervous system stimulants in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics 2007, 120:e1494-e1501.